

Preferred product: fingolimod

## **Pre - PA Allowance**

None

## **Prior-Approval Requirements**

**Age** 10 years of age or older

## **Diagnosis**

Patient must have the following:

Relapsing Multiple Sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease

#### **AND ALL** of the following:

- Member must be observed for 6 hours after the first dose for signs and symptoms of bradycardia with hourly pulse and blood pressure measurements and an ECG prior to dosing and at the end of the observation period
- 2. Prescriber has reviewed baseline complete blood count (CBC) including lymphocyte count
- 3. **NO** history (within the last 6 months) of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure
- 4. **NO** history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a pacemaker
- 5. **NO** significant QTc prolongation (QTc greater than or equal to 500 msec)
- 6. Patients with a history of uveitis and/or diabetes **ONLY**: will have an ophthalmic evaluation of the fundus, including the macula, prior to initiation of therapy
- 7. NO concurrent use with other MS disease modifying agents
- 8. **NOT** given concurrently with live vaccines
- 9. **Tascenso ODT only**: Patient is unable to swallow or has difficulty swallowing capsules
- 10. **Brand Gilenya 0.5mg only, Age 10-17**: Patient **MUST** have tried fingolimod (generic Gilenya) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance,



Preferred product: fingolimod

contraindication)

11. **Brand Gilenya 0.5mg only, Age 18+**: Patient **MUST** have tried fingolimod (generic Gilenya) **AND ONE** of the other preferred MS medications (see Appendix 1) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

# Prior - Approval Limits **Quantity**

Medication/Strength	Quantity Limit
Gilenya 0.25 mg capsule	90 units per 90 days <b>OR</b>
Gilenya 0.5 mg capsule	90 units per 90 days <b>OR</b>
Tascenso 0.25 mg ODT	90 units per 90 days
Tascenso 0.5 mg ODT	

**Duration** 12 months

\_\_\_\_\_\_

# Prior – Approval Renewal Requirements

Age 10 years of age or older

#### **Diagnosis**

Patient must have the following:

Relapsing Multiple Sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease

## **AND ALL** of the following:

- 1. **NO** history (within the last 6 months) of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure.
- 2. **NO** history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a pacemaker
- 3. **NO** significant QTc prolongation (QTc greater than or equal to 500 msec)
- 4. NO concurrent use with other MS disease modifying agents
- 5. **NOT** given concurrently with live vaccines
- 6. Brand Gilenya 0.5mg only, Age 10-17: Patient MUST have tried



Preferred product: fingolimod

fingolimod (generic Gilenya) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

7. **Brand Gilenya 0.5mg only, Age 18+**: Patient **MUST** have tried fingolimod (generic Gilenya) **AND ONE** of the other preferred MS medications (see Appendix 1) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

# Prior - Approval Renewal Limits

Same as above



Preferred product: fingolimod

## Appendix 1 - List of Preferred Multiple Sclerosis (MS) Medications for Age 18+

Medication Name	Route of Administration
Aubagio	Oral**
dimethyl fumarate (generic Tecfidera)	Oral**
fingolimod* (generic Gilenya)  *must try this drug plus one other preferred  MS medication oral or injectable	Oral
Mayzent	Oral**
Zeposia	Oral**

<sup>\*\*</sup> indicates separate criteria will need to be met

Medication Name	Route of Administration
Avonex	Injectable
Betaseron	Injectable
glatiramer acetate (generic Copaxone)	Injectable
Glatopa	Injectable
Plegridy	Injectable
Rebif	Injectable